Top Pharmaceutical Companies (2,035)
Mednow is a Vancouver, British Columbia-based healthcare technology company and Canada's full-service online pharmacy. It operates a proprietary web and mobile application to facilitate the sale and distribution of prescription medications and provides fast advice from certified pharmacists through a digital-first environment, optimizing delivery through modern digital platforms and last-mile logistics.
Orlando Senior Health Network is a nonprofit senior healthcare network dedicated to providing high-quality senior living and healthcare services, aiming to be the trusted leader in the field.
Aptahem AB (publ) is a biotechnology company engaged in the development of ribonucleic acid-based pharmaceuticals in Sweden.
OPIS was founded in 1998 by medical doctors from the Pharma Industry and is a Global clinical CRO with 25 years of experience in a wide range of therapeutic areas. OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling and up to study closure, analysis, and reporting. We...
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than...
Ferring Pharmaceuticals's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 revenues exceeded €2.5 billion, rising versus 2024 with notable momentum in the U.S. and key contributions from Menopur and Adstiladrin. Company disclosures and the annual report indicate continued year-over-year top-line expansion.
Innovation-Driven Growth: First-in-class approvals (Rebyota in microbiome therapeutics and Adstiladrin in bladder-cancer gene therapy) and WHO-recognized maternal-health innovation (heat-stable carbetocin) demonstrate differentiated science translating into commercial progress. FDA clearance of a second U.S. Adstiladrin site supports scaling these innovations.
Strong Market Position & Advantage: Leadership in ART/fertility and first-mover status in microbiome therapeutics and intravesical gene therapy provide competitive advantages in defined niches. This positioning underpins recent growth in core franchises.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
Regeneron's Top Stability & Growth Strengths
Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.
With 30+ years of experience, 28+ locations, and 2,000+ clinical studies conducted, Elite Clinical Network (ECN) is a trusted leader in clinical research. Our dedicated network of research sites is built on personalized service, investigator diversity, and rigorous quality processes to ensure excellence in every study. Backed by a professional corporate management team, we partner with top physicians across diverse specialties...
Solaris Pharma Corporation is a leading specialty pharmaceutical company committed to the identifying, developing, and marketing of high-quality, complex generic and specialty pharmaceutical products. The company aims to be a pacesetter in the niche pharmaceutical market by developing a broad portfolio of such products, providing patients with high-quality, affordable, effective, and value-added options.
Forge Biologics is a gene therapy contract development and manufacturing organization (CDMO) that helps bring transformative treatments from concept to patients. It provides scalable plasmid and AAV manufacturing, process and analytical development, cGMP production, fill-finish, quality, stability, and regulatory support. The company operates the Hearth, a large Columbus, Ohio facility designed to accelerate development of therapies for genetic diseases more...
First Choice Community Health Centers (FCCHC) is a non-profit primary healthcare facility based in Lillington, NC. It is dedicated to providing primary health care, dental, and pharmaceutical services to the underserved citizens of Harnett and surrounding counties. Its mission is to provide comprehensive health care services with excellence and compassion for the entire community, focusing on breaking down social and...
August Bioservices is a Contract Development and Manufacturing Organization (CDMO) headquartered in Nashville, Tennessee. August Bio offers a full range of pharmaceutical contract development and manufacturing services to pharmaceutical and biotech clients. We focus on sterile injectables, topicals, highly-complex formulations, poorly soluble & highly viscous compounds, Uncommon container sizes & fill volumes and offer aseptic and non-aseptic terminally sterilized filling...
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia, focusing on maternal and fetal medicine to lower risks for mothers and babies.
Genfar S.A., founded in 1967 in Colombia, is a pharmaceutical company dedicated to the development, manufacturing, and wholesale distribution of high-quality and affordable medicines for human and animal health. Focused on expanding access to healthcare across Latin America, the company operates in Colombia, Peru, and Ecuador, providing a broad portfolio of generic and prescription drugs characterized by their quality and...
A leading applied technology services company, we innovate to deliver service excellence and successful outcomes across sales, delivery and development. With our strategy to be agile, nimble and customer-centric, we anticipate the future of applied technology and predict tomorrow’s trends to keep our clients at the summit in an ever-changing marketplace. Leading with architecture and design, our next-gen solutions enable...
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments...
BioMarin Pharmaceutical Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Results show double‑digit revenue growth in 2025, with acceleration in Q4 driven by Voxzogo uptake and steady enzyme therapies across 55 markets. 2026 guidance points to a higher revenue range, indicating continued expansion.
Profitability: Disclosures highlight strong profitability with $828 million in 2025 operating cash flow and a targeted ~40% non‑GAAP operating margin for 2026 (excluding Amicus). Non‑GAAP EPS guidance of $4.95–$5.15 further signals operating leverage.
Diversified Revenue Streams: The portfolio spans multiple enzyme therapies and the achondroplasia franchise, and the pending Amicus acquisition would add Galafold and Pombiliti + Opfolda to diversify revenues from mid‑2026 onward. Enzyme therapies collectively grew in 2025, supporting breadth beyond a single asset.
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated...
theMednet is the premier peer-to-peer digital platform helping physicians unlock expert knowledge. Our mission is to facilitate knowledge and information sharing between physicians and help address disparities in patient care. theMednet is a physician-only network to access invaluable expert advice and request answers to real world clinical questions. All content serves as a resource for physicians to access expert knowledge, contribute...
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 85 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products...
SHINE Medical Technologies, LLC is a nuclear technology company focused on developing and producing medical isotopes for diagnostic and therapeutic purposes using fusion technology. They also aim to generate carbon-free energy from nuclear fusion.
